BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

870 related articles for article (PubMed ID: 27089005)

  • 1. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Zacharias HD; Kamel F; Tan J; Kimer N; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011585. PubMed ID: 37467180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonabsorbable disaccharides for hepatic encephalopathy.
    Als-Nielsen B; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2004; (2):CD003044. PubMed ID: 15106187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probiotics for patients with hepatic encephalopathy.
    McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
    Goh ET; Andersen ML; Morgan MY; Gluud LL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
    Goh ET; Andersen ML; Morgan MY; Gluud LL
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD002798. PubMed ID: 28796283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotics for people with hepatic encephalopathy.
    Dalal R; McGee RG; Riordan SM; Webster AC
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008716. PubMed ID: 28230908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
    Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD011451. PubMed ID: 30610762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
    Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.
    Als-Nielsen B; Gluud LL; Gluud C
    BMJ; 2004 May; 328(7447):1046. PubMed ID: 15054035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osmotic and stimulant laxatives for the management of childhood constipation.
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009118. PubMed ID: 22786523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.
    Vadera S; Yong CWK; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012673. PubMed ID: 31220333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.